The Prognostic Potential of Neurokinin 1 Receptor in Breast Cancer and Its Relationship with Ki-67 Index

Table 1

Demographic, clinical, and histopathological characteristics of 164 breast cancer patients.

Variable	Total (%)
Age (years)
Mean ± SD
Range	28-82
Molecular subtype
HER2-enriched	42 (25.6)
Luminal A	40 (24.4)
Luminal B	42 (25.6)
Triple negative	40 (24.4)
Grade
I	8 (4.9)
II	46 (28)
III	110 (67.1)
Tumor volume (cm^3)
Mean ± SD
Range	0.18-571.77
TNM stage
I	7 (4.3)
II	45 (27.4)
III	56 (34.1)
IV	54 (32.9)
Missing	2 (1.2)
pT stage
T1	13 (7.9)
T2	88 (53.7)
T3	47 (28.7)
T4	16 (9.8)
pN stage
N0	44 (26.8)
N1	39 (23.8)
N2	33 (20.1)
N3	43 (26.2)
Missing	5 (3.0)
Distant metastasis
M0	108 (65.9)
M1	54 (32.9)
Missing	2 (1.2)
Axillary lymph node metastasis
Negative	45 (27.4)
Positive	117 (71.3)
Missing	2 (1.2)
Lymphovascular invasion
Negative	31 (18.9)
Positive	94 (57.3)
Missing	39 (23.8)
ER status
Negative	82 (50)
Positive	82 (50)
PR status
Negative	82 (50)
Positive	82 (50)
HER2 status
Negative	80 (48.8)
Positive	84 (51.2)
DCIS history
Absent	27 (16.5)
Present	113 (68.9)
Missing	24 (14.6)
Family history
No	106 (64.6)
Yes	29 (17.7)
Missing	29 (17.7)
Adjuvant chemotherapy
No	4 (2.4)
Yes	120 (73.2)
Missing	40 (24.4)
Adjuvant radiotherapy
No	75 (45.7)
Yes	49 (29.9)
Missing	40 (24.4)
Hormonal therapy
No	62 (37.8)
Yes	62 (37.8)
Missing	40 (24.4)
Immunotherapy
No	118 (72.0)
Yes	6 (3.7)
Missing	40 (24.4)
Ki-67 index
Low	96 (58.5)
High	68 (41.5)
NK1R
Low	108 (65.9)
High	56 (34.1)

DCIS: ductal carcinoma in situ; ER: estrogen receptor; PR: progesterone receptor; NK1R: neurokinin 1 receptor.